Skip to content

Mirum Pharmaceuticals, Inc. MIRM Other income, net (Note 6)

Other income, net (Note 6) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$456K-198%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
Arrowhead Research logo
Arrowhead ResearchARWR
Alkermes logo
AlkermesALKS
TG Therapeutics logo
TG TherapeuticsTGTX
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s other income, net (note 6)?
Mirum Pharmaceuticals, Inc. (MIRM) reported other income, net (note 6) of $0 in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s other income, net (note 6) changed year-over-year?
Mirum Pharmaceuticals, Inc.'s other income, net (note 6) decreased by 100.0% year-over-year, from $2.11M to $0.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s other income, net (note 6)?
Over 3 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s other income, net (note 6) has grown at a 64.5% compound annual growth rate (CAGR), from -$582K to $2.59M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.